TRENDING: See Nvidia's Growing Appetite For Startup Investments Hims stock popped Wednesday after the telemedicine giant announced its long-awaited foray into offering testosterone replacement therapy. The announcement was highly anticipated given Hims & Hers Health (HIMS) has long discussed its plan to launch a testosterone replacement therapy, or TRT. There will be four options, offered in partnership with privately held Marius Pharmaceuticals. Pricing has yet to be outlined, but will likely run in the ra ...

Hims & Hers Health Inc. HIMS launched a new category in men’s health on Wednesday, offering access to affordable and personalized treatment plans for low testosterone.An estimated 20 million men in the U.S. struggle with low testosterone.Bloomberg earlier reported the update. The telehealth company's latest move comes as its weight-loss drug sales have slowed, impacting its stock performance in recent months. The new offerings aim to bolster its core sexual health services and tap into an underserved market ...